In vitro and in vivo protective effect of orphenadrine on glutamate neurotoxicity

Neuropharmacology

Volumn 38, Issue 5, 1999, Pages 671-677

  Sureda, Francesc X ^a   Gabriel, Cecília ^a   Pallàs, Mercè ^a   Adan, Jaume ^b   Maria Martínez, Josep ^b   Escubedo, Elena ^a   Camarasa, Jorge ^a   Camins, Antonio ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b S A Laboratorio de Bioinvestigacion   (Spain)

Author keywords

Excitotoxicity; Heat shock proteins; Neurodegeneration; Orphenadrine; Peripheral type benzodiazepine receptor; Rat

Indexed keywords

4' CHLORODIAZEPAM; BENZODIAZEPINE RECEPTOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIZOCILPINE; GLUTAMIC ACID; GRAMICIDIN; HEAT SHOCK PROTEIN 72; KAINIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; ORPHENADRINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL GRANULE; DRUG ACTIVITY; GRANULE CELL; HIPPOCAMPUS; IMMUNOBLOTTING; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MEMBRANE POTENTIAL; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR DENSITY;

ANIMALS; ANTIPARKINSON AGENTS; CELLS, CULTURED; CEREBELLUM; EXCITATORY AMINO ACID AGONISTS; HIPPOCAMPUS; KAINIC ACID; MALE; MEMBRANE POTENTIALS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; ORPHENADRINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0033055438     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00228-7     Document Type: Article

References (29)

1. Altamura A.C., Buccio M., Colacurcio F., Colombo G., Terzi A. Orphenadrine plasma levels and amelioration of extrapyramidal side effects in schizophrenic patients treated with haloperidol. Acta Neurol. Napoli. 8:1986;19-26.
2. Ankarcrona M., Dypbukt J.M., Bonfoco E., Zhivotovsky B., Orrenius S., Lipton S.A., Nicotera P. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron. 15:1995;961-973.
3. Bénavidès J., Fage D., Carter C., Scatton B. Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage. Brain Res. 421:1987;167-172.
4. Bénavidès J., Capdeville C., Dauphin F., Dubois A., Duverger D., Fage D., Gotti B., MacKenzie E.T., Scatton B. The quantification of brain lesions with an omega 3 site ligand: a critical analysis of animal models of cerebral ischemia and neurodegeneration. Brain Res. 522:1990;275-289.
5. Bénavidès J., Bourdiol F., Dubois A., Scatton B. Regional pattern of increased omega 3 (peripheral type benzodiazepine) binding site densities in the rat brain induced by systemic injection of kainic acid. Neurosci. Lett. 125:1991;219-222.
6. Blandini F., Porter R.H., Greenamyre J.T. Glutamate and Parkinson's disease. Mol. Neurobiol. 12:1996;73-94.
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
8. Brouillet E., Beal M.F. NMDA antagonists partially protect against MPTP induced neuroxicity in mice. Neurochemistry. 4:1993;387-390.
9. Camins A., Sureda F.X., Gabriel C., Pallàs M., Escubedo E., Camarasa J. Modulation of neuronal mitochondrial membrane potential by the NMDA receptor: role of arachidonic acid. Brain Res. 777:1997;69-74.
10. Camins A., Gabriel C., Aguirre L., Sureda F.X., Pubill D., Pallas M., Escubedo E., Camarasa J. U-83836E prevents kainic acid-induced neuronal damage. Naunyn Schmiedebergs Arch. Pharmacol. 357:1998;413-418.
11. Contin M., Riva R., Albani F., Baruzzi A. Simple and rapid GLC method for the determination of orphenadrine in human plasma. Biomed. Chromatogr. 2:1987;193-194.
12. Cooper A.J., Carroll C.B., Mitchell I.J. Glutamate antagonist for Parkinson's disease. Rationale for use and therapeutic implications. Drugs. 9:1998;421-429.
13. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci. Biobehav. Rev. 21:1997;455-468.
14. Gallo V., Kingsbury A., Balazs R., Jorgensen O.S. The role of depolarization in the survival and differentiation of cerebellar granule cells in culture. J. Neurosci. 7:1987;2203-2213.
15. Gonzalez M.F., Shiraishi K., Hisanaga K., Sagar S.M., Mandabach M., Sharp F.R. Heat shock proteins as markers of neural injury. Brain Res. Mol. Brain Res. 6:1989;93-100.
16. Jackisch R., Kruchen A., Sauermann W., Hertting G., Feuerstein T.J. The antiparkinsonian drugs budipine and biperiden are use-dependent (uncompetitive) NMDA receptor antagonists. Eur. J. Pharmacol. 264:1994;207-211.
17. Klockgether T., Jacobsen P., Loschmann P.A., Turski L. The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J. Neural. Transm. P-D Sect. 5:1993;101-106.
18. Kornhuber J., Parsons C.G., Hartmann S., Retz W., Kamolz S., Thome J., Riederer P. Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies. J. Neural. Transm. Sect. 102:1995;237-246.
19. Laurie D.J., Seeburg P.H. Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. Eur. J. Pharmacol. 268:1994;335-345.
20. Liu Z., Stafstrom C.E., Sarkisian M.R., Yang Y., Hori A., Tandon P., Holmes G.L. Seizure-induced glutamate release in mature and immature animals: an in vivo microdialysis study. Neuroreport. 8:1997;2019-2023.
21. Planas A.M., Soriano M.A., Ferrer I., Rodriguez-Farre E. Kainic acid-induced heat shock protein-70, mRNA and protein expression is inhibited by MK-801 in certain rat brain regions. Eur. J. Neurosci. 7:1995;293-304.
22. Sloviter R.S., Lowenstein D.H. Heat shock protein expression in vulnerable cells of the rat hippocampus as an indicator of excitation-induced neuronal stress. J. Neurosci. 12:1992;3004-3009.
23. Soriano M.A., Ferrer I., Rodriguez-Farre E., Planas A.M. Expression of c-fos and inducible hsp-70 mRNA following a transient episode of focal ischemia that had non-lethal effects on the rat brain. Brain Res. 670:1995;317-320.
24. Sureda F.X., Camins A., Trullas R., Camarasa J., Escubedo E. A flow cytometric study of N-methyl-D-aspartate effects on dissociated cerebellar cells. Brain Res. 723:1996;110-114.
25. Sureda F.X., Escubedo E., Gabriel C., Camarasa J., Camins A. Effect of glutamate receptor ligands on mitochondrial membrane potential in rat dissociated cerebellar cells. Naunyn Schmiedeberg's Arch. Pharmacol. 354:1996;420-423.
26. Sureda F.X., Escubedo E., Gabriel C., Comas J., Camarasa J., Camins A. Mitochondrial membrane potential measurement in rat cerebellar neurons by flow cytometry. Cytometry. 28:1997;74-80.
27. Starr M.S. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse. 19:1995;264-293.
28. Streit W.J. The role of microglia in brain injury. Neurotoxicology. 17:1996;671-678.
29. Syapin P.J., Alkana R.L. Chronic ethanol exposure increases peripheral-type benzodiazepine receptors in brain. Eur. J. Pharmacol. 147:1988;101-109.